[1]肖吉,陈文,刘玉元,等.拉米夫定治疗HBeAg阴性慢性乙型肝炎疗效相关因素分析[J].陆军军医大学学报(原第三军医大学学报),2011,33(08):835-837.
 Xiao Ji,Chen Wen,Liu Yuyuan,et al.Analysis of factors related to lamivudine efficacy in treating HBeAg-negative chronic hepatitis B[J].J Amry Med Univ (J Third Mil Med Univ),2011,33(08):835-837.
点击复制

拉米夫定治疗HBeAg阴性慢性乙型肝炎疗效相关因素分析(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
33卷
期数:
2011年第08期
页码:
835-837
栏目:
论著
出版日期:
2011-04-30

文章信息/Info

Title:
Analysis of factors related to lamivudine efficacy in treating HBeAg-negative chronic hepatitis B
作者:
肖吉陈文刘玉元王宇明
第三军医大学西南医院全军感染病研究所
Author(s):
Xiao Ji Chen Wen Liu Yuyuan Wang Yuming
Institute of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China
关键词:
拉米夫定HBeAg阴性肝炎相关因素
Keywords:
lamivudine HBeAg-negative chronic hepatitis B HBV DNA risk factor
分类号:
R512.620.5;R978.7;R446.9
文献标志码:
A
摘要:
目的    研究分析影响拉米夫定治疗HBeAg阴性慢性乙型病毒性肝炎疗效的主要相关因素。    方法    收集2006年1月至2009年12月在我科和门诊就诊并接受拉米夫定治疗的HBeAg阴性慢性乙型肝炎203例患者临床资料,分析患者治疗前性别、年龄、血清ALT水平、HBV DNA水平、基因型等因素与疗效的相关性。    结果    获得病毒学应答患者为180例(88.7%),应答患者较之无应答患者基线HBV DNA水平较低;长期治疗时发生病毒学突破患者为81例(45%),发生病毒学突破患者较之获得持续应答的患者基线 HBV DNA水平较高;COX比例风险回归模型分析认为,治疗前HBV DNA水平以及治疗6个月时HBV DNA状态是发生病毒学突破的危险因素。    结论    拉米夫定治疗HBeAg阴性慢性乙型病毒性肝炎过程中,治疗前较低的HBV DNA水平能够获得较好的应答,治疗6个月时HBV DNA阳性状态是病毒学突破的高危因素。
Abstract:
Objective    To study the factors related to lamivudine efficacy in treating hepatitis B e-antigen (HBeAg)-negative chronic hepatitis B.     Methods    The clinical data of 203 HBeAg-negative chronic hepatitis B patients who received lamivudine treatment in our hospital were collected from Jan. 2006 to Dec. 2009. The correlation of lamivudine efficacy with factors before therapy, such as gender, age, blood serum alanine transaminase (ALT) level, blood serum hepatitis B virus (HBV) DNA level, and HBV genotype, was analyzed.     Results    Among the 203 patients, 180 (88.7%) achieved virological response and exhibited a lower baseline HBV DNA level than those without virological response. During long-term therapy of the 180 cases, 81 (45%) experienced virological breakthrough and exhibited a higher baseline HBV DNA level than those with continuous virological response. Cox proportional-hazards regression model analysis results showed that HBV DNA level before therapy and HBV DNA positive in the 6th month of therapy were risk factors associated with virological breakthrough.     Conclusion    During lamivudine treatment of HBeAg-negative chronic hepatitis B, a lower HBV DNA level before therapy can result in better response. HBV DNA positive in the 6th month of therapy is a high risk factor associated with virological breakthrough.

相似文献/References:

[1]张南,夏杰,邓国宏,等.拉米夫定对慢性重型乙型肝炎患者生存率的提高[J].陆军军医大学学报(原第三军医大学学报),2008,30(01):75.
 ZHANG Nan,XIA Jie,DENG Guo-hong,et al.Effect of lamivudine on survival rate of patients with chronic severe hepatitis B[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(08):75.
[2]张耀,郑莎,周吉军,等.拉米夫定治疗乙型肝炎病毒相关性肝衰竭疗效的Meta分析[J].陆军军医大学学报(原第三军医大学学报),2008,30(09):848.
 ZHANG Yao,ZHENG Sha,ZHOU Ji-jun,et al.Efficacy of lamivudine in treatment on HBV-related liver failure:Meta analysis study[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(08):848.
[3]李玲,毛青,黄燕萍,等.慢性乙型肝炎患者HBV DNA YMDD变异的检测及意义[J].陆军军医大学学报(原第三军医大学学报),2005,27(02):167.
[4]何登明,毛青,王宇明,等.拉米夫定疗程中慢性乙型肝炎患者血清IL-12水平和Th平衡变化及其意义[J].陆军军医大学学报(原第三军医大学学报),2004,26(19):0.[doi:10.16016/j.1000-5404.2004.19.028 ]
 HE Deng-ming,MAO Qing,WANG Yu-ming,et al.[J].J Amry Med Univ (J Third Mil Med Univ),2004,26(08):0.[doi:10.16016/j.1000-5404.2004.19.028 ]
[5]黄燕萍,王宇明.拉米夫定治疗50例慢性乙型肝炎患者自身前后对照试验[J].陆军军医大学学报(原第三军医大学学报),2002,24(11):0.[doi:10.16016/j.1000-5404.2002.11.055 ]
 HUANG Yan ping,WANG Yu ming.[J].J Amry Med Univ (J Third Mil Med Univ),2002,24(08):0.[doi:10.16016/j.1000-5404.2002.11.055 ]

更新日期/Last Update: 2011-04-13